Satsuma Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
18 May, 2023
Q4 2022
16 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Satsuma Pharmaceuticals Inc
Access all reports
Satsuma Pharmaceuticals Inc is a development-stage biopharmaceutical company focused on innovating therapeutic products for people suffering from migraine and other debilitating conditions. Its primary product candidate is STS101, a dihydroergotamine (DHE) nasal powder, aimed at offering a significant and differentiated treatment option for acute migraine attacks. Satsuma Pharmaceuticals is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
STSA
Country
🇺🇸 United States